Background/Aims: Adefovir dipivoxil treatment leads to higher HBeAg seroconversion rates than placebo. The study was to evaluate which clinical or virological variables correlate with endpoints (e.g. HBeAg seroconversion and HBV DNA <105 copies/mL) during Adefovir dipivoxil or placebo therapy. Methodology: Fifty-two patients were enrolled with 33 in the ADV group and 19 in the placebo group. The correlation between clinical/virological variables and endpoints was evaluated by logistic regression as well as stratified analyses using Fisher's exact test. Results: After one year of treatment, HBeAg seroconversion was associated with low pre-treatment HBV DNA levels. HBeAg seroconversion rates categorized by pre-treatment HBV DNA levels were distinct in the placebo group (<107 vs. >107 copies/mL, P=0.037) and in the ADV group (<108 vs. >108 copies/mL, P=0.039). In addition, HBV DNA levels reductions at week 4, week 8 and week 12 were associated with higher rates of HBeAg seroconversion. Conclusions: Low pre-treatment HBV DNA level is predictive of HBeAg seroconversion in patients treated with Adefovir dipivoxil or placebo. Adefovir dipivoxil may provide additional benefits for HBeAg seroconversion in patients with pre-treatment HBV DNA levels between 107 and 108 copies/mL. Profound early HBV DNA reduction may contribute to HBeAg seroconversion.
|Number of pages||6|
|Publication status||Published - 2009 May 1|
All Science Journal Classification (ASJC) codes